See more : Kilburn Engineering Limited (KLBRENG-B.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Seres Therapeutics, Inc. (MCRB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Seres Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Brangista Inc. (6176.T) Income Statement Analysis – Financial Results
- Zaptec AS (6I4.F) Income Statement Analysis – Financial Results
- Doctor Care Anywhere Group PLC (DOC.AX) Income Statement Analysis – Financial Results
- Media 100 Inc. (MDEA) Income Statement Analysis – Financial Results
- Faurecia S.E. (EO.MI) Income Statement Analysis – Financial Results
Seres Therapeutics, Inc. (MCRB)
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 126.33M | 7.13M | 144.93M | 33.22M | 34.51M | 28.27M | 32.10M | 21.77M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 704.00K | 1.00M | 1.73M | 90.57M | 80.14M | 95.96M | 89.46M | 81.99M | 728.00K | 10.72M | 0.00 | 0.00 |
| Gross Profit | 125.62M | 6.12M | 143.20M | -57.36M | -45.64M | -67.69M | -57.36M | -60.22M | -728.00K | -10.72M | 0.00 | 0.00 |
| Gross Profit Ratio | 99.44% | 85.91% | 98.80% | -172.68% | -132.26% | -239.46% | -178.68% | -276.68% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 145.86M | 172.92M | 141.89M | 90.57M | 80.14M | 95.96M | 89.46M | 81.99M | 38.10M | 10.72M | 4.81M | 2.08M |
| General & Administrative | 87.74M | 79.69M | 69.26M | 30.78M | 24.75M | 32.60M | 34.04M | 32.62M | 16.76M | 4.36M | 1.25M | 956.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 87.74M | 79.69M | 69.26M | 30.78M | 24.75M | 32.60M | 34.04M | 32.62M | 16.76M | 4.36M | 1.25M | 956.00K |
| Other Expenses | 0.00 | 1.00M | -1.73M | 981.00K | 1.07M | 170.00K | 425.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 233.60M | 253.62M | 209.42M | 121.35M | 104.89M | 128.55M | 123.50M | 114.61M | 54.86M | 15.08M | 6.05M | 3.03M |
| Cost & Expenses | 234.31M | 253.62M | 209.42M | 121.35M | 104.89M | 128.55M | 123.50M | 114.61M | 54.86M | 15.08M | 6.05M | 3.03M |
| Interest Income | 7.30M | 3.06M | 2.87M | 946.00K | 1.03M | 0.00 | 0.00 | 2.23M | 638.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.18M | 6.02M | 2.91M | 2.92M | 502.00K | 1.17M | 1.59M | 969.00K | 555.00K | 0.00 | 42.00K | 0.00 |
| Depreciation & Amortization | 6.24M | 11.85M | 9.22M | 8.89M | 9.83M | 7.86M | 7.26M | 4.21M | 728.00K | 190.00K | 88.00K | 25.00K |
| EBITDA | -94.31M | -237.51M | -56.72M | -77.31M | -59.95M | -91.08M | -82.12M | -88.63M | -54.13M | -14.89M | -5.96M | -3.01M |
| EBITDA Ratio | -74.65% | -3,425.04% | -43.24% | -259.53% | -197.90% | -354.77% | -262.11% | -396.97% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -107.98M | -246.49M | -64.49M | -88.13M | -71.88M | -100.28M | -91.40M | -92.84M | -54.86M | -15.08M | -6.05M | -3.03M |
| Operating Income Ratio | -85.48% | -3,458.05% | -44.50% | -265.33% | -208.31% | -354.77% | -284.72% | -426.53% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.74M | -3.67M | -1.09M | -997.00K | 1.60M | 1.34M | 2.02M | 1.26M | 76.00K | -1.63M | -50.00K | -93.00K |
| Income Before Tax | -113.72M | -250.16M | -65.58M | -89.13M | -70.28M | -98.94M | -89.38M | -91.58M | -54.78M | -16.71M | -6.10M | -3.13M |
| Income Before Tax Ratio | -90.02% | -3,509.50% | -45.25% | -268.33% | -203.68% | -350.03% | -278.44% | -420.74% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.67M | -4.08M | -2.67M | -6.04M | 1.34M | -1.59M | 2.23M | -804.00K | 1.63M | 42.00K | 0.00 |
| Net Income | -113.72M | -253.82M | -61.50M | -86.45M | -64.24M | -98.94M | -89.38M | -91.58M | -54.78M | -16.71M | -6.10M | -3.13M |
| Net Income Ratio | -90.02% | -3,560.94% | -42.43% | -260.29% | -186.19% | -350.03% | -278.44% | -420.74% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.89 | -2.35 | -0.67 | -1.08 | -1.13 | -2.43 | -2.21 | -2.30 | -2.33 | -0.56 | -0.20 | -0.15 |
| EPS Diluted | -0.89 | -2.35 | -0.67 | -1.08 | -1.13 | -2.43 | -2.21 | -2.30 | -2.33 | -0.56 | -0.20 | -0.15 |
| Weighted Avg Shares Out | 128.00M | 108.08M | 91.70M | 79.79M | 56.65M | 40.74M | 40.45M | 39.85M | 23.53M | 29.78M | 29.78M | 20.68M |
| Weighted Avg Shares Out (Dil) | 128.00M | 108.08M | 91.70M | 79.79M | 56.65M | 40.74M | 40.45M | 39.85M | 23.53M | 29.78M | 29.78M | 20.68M |
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)
Source: https://incomestatements.info
Category: Stock Reports